Clinical trial · Interventional
Technology-Enhanced Palliative Care for Advanced Cancer Patients
Technology-Enhanced Palliative Care for Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial investigates technology-enhanced palliative care for patients in phase I trials with cancer that has spread to other places in the body (advanced). The goal of this study is to learn if the technology-enhanced palliative care symptom-monitoring program, when combined with in-person clinic visits and standard remote care visits (by phone or video call), helps increase quality of life and care for patients with advanced cancer participating in phase 1 immunotherapy trials.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Malignant Solid Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Other | — | UNRESOLVED |
| Palliative Therapy | Other | — | UNRESOLVED |
| Quality-of-Life Assessment | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Arm I (standard symptom management)
- description
- Patients receive standard symptom management by palliative care team once every 4 weeks for 12 weeks. Patients and caregivers also may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
- interventionNames
- Other: Interview
- Other: Palliative Therapy
- Other: Quality-of-Life Assessment
- type
- EXPERIMENTAL
- label
- Arm II (weekly provider-initiated remote contact)
- description
- Patients in Phase I immunotherapy trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact every week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
- interventionNames
- Other: Interview
- Other: Palliative Therapy
- Other: Quality-of-Life Assessment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * PATIENT: Diagnosis of advanced solid tumor * PATIENT: Oncologic plan for a phase I trial * PATIENT: High symptom burden (defined as a score of \>= 4 on at least 1 Edmonton Symptom Assessment Scale \[ESAS\] symptom, AND a global distress score \[GDS\] of \>= 20) * PATIENT: Reliable telephone and internet access * PATIENT: Able to communicate verbally in English and provide informed consent * CAREGIVER: Able to communicate verbally in English and provide informed consent * CAREGIVER: Reliable telephone and internet access Exclusion Criteria: * PATIENT: Low symptom burden defined as scores \< 4 on all ESAS symptoms OR GDS \< 20 * PATIENT: Delirium (i.e. Memorial Delirium Assessment Scale \> 8) * PATIENT: No reliable telephone or internet access * CAREGIVER: Refusal to participate in this study * CAREGIVER: No reliable telephone or internet access
References
Publications (0)
Data not yet available